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Evaluation of Glutathione Metabolic Genes on Outcomes
in Advanced Non-small Cell Lung Cancer Patients after
Initial Treatment with Platinum-Based Chemotherapy
An NCCTG-97-24-51 Based Study
Ping Yang, MD, PhD,* Sumithra J. Mandrekar, PhD,* Shauna H. Hillman, MS,*
Katie L. Allen Ziegler, BS,* Zhifu Sun, MD, MS,* Jason A. Wampfler, BS,*
Julie M. Cunningham, PhD,* Jeff A. Sloan, PhD,* Alex A. Adjei, MD, PhD,*† Edith Perez, MD,*
and James R. Jett, MD*
Introduction: We evaluated the role of glutathione-related geno-
types on overall survival, time to progression, adverse events, and
quality of life (QOL) in stage IIIB/IV non-small cell lung cancer
patients who were stable or responding from initial treatment with
platinum-based chemotherapy and subsequently randomized to re-
ceive daily oral carboxyaminoimidazole or a placebo.
Methods: Of the 186 total patients, 113 had initial treatment with
platinum therapy and DNA samples of whom 46 also had QOL data.
These samples were analyzed using six polymorphic DNA markers
that encode five important enzymes in the glutathione metabolic
pathway. Patient QOL was assessed using the Functional Assess-
ment of Cancer Therapy-Lung and the UNISCALE QOL question-
naires. A clinically significant decline in QOL was defined as a 10%
decrease from baseline to week-8. Multivariate analyses were used
to evaluate the association of the genotypes on the four endpoints.
Results: Patients carrying a GCLC 77 genotype had a worse overall
survival (hazard ratio (HR)  1.5, p  0.05). Patients carrying the
GPX1-CC genotype had a clinically significant decline in the UNIS-
CALE (odds ratio (OR): 7.5; p 0.04), total Functional Assessment of
Cancer Therapy-Lung score (OR: 11.0; p  0.04), physical (OR: 7.1;
p  0.03), functional (OR: 5.2; p  0.04), and emotional well-being
constructs (OR: 23.8; p  0.01).
Conclusions: Genotypes of glutathione-related enzymes, especially
GCLC, may be used as host factors in predicting patients’ survival
after platinum-based chemotherapy. GPX1 may be an inherited
factor in predicting patients’ QOL. Further investigation to define
and measure the effects of these genes in chemotherapeutic regi-
mens, drug toxicities, disease progression, and QOL are critical.
Key Words: Gluthathione metabolic genes, Non small cell lung
cancer, Platinum-based chemotherapy.
(J Thorac Oncol. 2009;4: 479–485)
Platinum-based compounds remain the most commonlyused chemotherapeutic agents in the treatment of ad-
vanced-stage lung cancer patients, and the glutathione (GSH)
metabolic pathway is directly involved in the inactivation of
platinum compounds.1 Specifically, elevated GSH and/or
GSH-dependent enzyme levels (denoted as high or positive)
may correlate with inferior treatment response, and inhibition
or reduction of GSH and/or GSH-dependent enzymes in-
creases treatment response rates. Our earlier work indicated
that 1-year survival rates were 60 to 78% for patients with
high and/or positive genotypes compared with 89 to 100% for
other types; the survival advantage was greater among ad-
vanced-stage patients who carried other types than low-stage
patients.2 Particularly, in late-stage patients who undertook
platinum-based chemotherapy, a 3-nucleotide repeat poly-
morphism in GCS affected survival significantly; those with
a homozygous 77 repeat genotype had the worst survival
outcome, even after 5 years.3 However, these results have not
been replicated in prospective cohort studies nor clinical
trials. In the setting of a phase III trial (NCCTG-97-24-51),
we evaluated the role of GSH-related genotypes on clinical
outcomes and patient quality of life (QOL) in stage IIIB/IV
non-small cell lung cancer patients (NSCLC) who were stable
or responding to one initial treatment with a platinum-based
chemotherapy regimen.
MATERIALS AND METHODS
Data
Results from the NCCTG-97–24-51 trial have been
reported previously.4 Briefly, the trial drug, Carboxy-
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amidotriazole (CAI), NSC 609974, is a synthetic inhibitor of
both nonvoltage- and voltage-gated calcium pathways; more
detailed information of this drug and the trial have been
described in our earlier report,4 and summarized as follows.
CAI inhibits angiogenesis, tumor cell motility, adhesion, and
metastatic potential; it also decreases matrix metalloprotein-
ase-2/gelatinase A and basic epidermal growth factor in vitro;
and it reduces vascular endothelial growth factor and inter-
leukin-8 production in cancer animal models. In a phase I
clinical trial, disease stabilization and improvement in per-
formance status was reported in patients with refractory
cancers including NSCLC, who were treated with CAI. Pa-
tients were 18 years of age or older, histologically or cyto-
logically confirmed stage III or IV NSCLC, and had com-
pleted one and only one chemotherapy regimen (with or
without thoracic radiation) within the previous 6 weeks with
a resulting complete response, partial response, or stable
disease. Women who were pregnant, nursing, or not utilizing
adequate contraception; patients with untreated brain metas-
tases; and those with planned additional chemotherapy, ra-
diotherapy, or immunotherapy or participation in another
phase III trial were not eligible for this trial. All patients
signed a written informed consent that had been approved by
the Institutional Review Board of the treating institution.
Patients were assigned randomly to receive either oral CAI at
a dose of 250 mg daily or a placebo after completion of at
least 3 and no more than 6 months of one chemotherapy
regimen and demonstration of disease stability or regression/
response by the World Health Organization criteria. Treat-
ment with the study agent continued until disease progres-
sion, unacceptable adverse event (AE), or patient refusal. All
AEs were graded according to the National Cancer Institute’s
Common Toxicity Criteria (version 2.0).5 The UNISCALE6
and the Functional Assessment of Cancer Therapy-Lung
(FACT-L)7 were used to assess patient QOL. Patients com-
pleted the questionnaires at baseline and after every 8 weeks
(2 cycles) of treatment before the assessment by the treating
physician.
Between April 1999 and January 2004, 186 patients
(CAI 94, placebo 92) were randomized to receive either CAI
or a placebo. The primary study results demonstrated that the
addition of CAI after chemotherapy did not provide clinical
benefit or improvement in QOL over a placebo in advanced
NSCLC. The current study was one of the ancillary correla-
tive components to evaluate the effects of patients’ inherited
variations in drug metabolizing pathways on disease out-
comes, either independent of or interactive with the chemo-
therapeutic agents. Although the trial was terminated too
early to reach the anticipated sample size for evaluating
potential genomic influence on responses to CAI, the
available samples were used to validate our previous
findings on the role of the GSH pathway genomic poly-
morphisms on survival of platinum-drug treated late stage
lung cancer patients.
Of the total 186 randomized patients, 145 had initial
treatment with platinum therapy (134 had carboplatin alone,
10 had cisplatin alone, and 1 had both), 148 had DNA
samples available for genotyping, and 111 had QOL assessed
at baseline and week-8 (50% of patients were evaluable for
QOL at the 16- and 24-week time points, due to ending
treatment). A total of 113 (76% of 148) patients had initial
treatment with platinum therapy and DNA samples geno-
typed (cohort I), and 46 patients had initial treatment with
platinum therapy, DNA samples genotyped, and baseline and
week-8 QOL data (cohort II) (Figure 1). All patients were off
active treatment at the time of this analysis. In terms of
subsequent treatment, 33% received no further treatment
for cancer, 34% received chemotherapy (C) alone, 8%
received radiation (RT) alone, and 25% received C along
with either: RT, surgery and RT, antibody, antibody and
RT, tyrosine kinase inhibitor (TKI), TKI and RT, and TKI,
antibody, and RT.
Analyses
Genotyping
DNA samples were analyzed using six polymorphic
DNA markers that encode five important enzymes in the GSH
metabolic pathway. Laboratory methods and assay descrip-
tions have been previously reported,2,8 using a polymerase
chain reaction-based Beckman single nucleotide polymor-
phism (SNPstream) genotyping system and TaqMan and ABI
fragment analysis performed by the Mayo Clinic Genotyping
Shared Resources Laboratory. The contrasting genotypes
used in the analysis were GCLC (homozygous repeat 77
versus heterozygous 7* versus **), GPX1 (CC versus other),
GSTP1-I105V (AA versus other), GSTP1-A114V (CC versus
other), GSTM1 (null versus present), and GSTT1 (null versus
present).
Quality of Life (QOL)
The UNISCALE6 and the FACT-L7 were used to assess
patient QOL. The FACT-L includes four separate constructs
of well-being namely physical, social/family, emotional, and
functional, and additional concerns, dealing solely with tumor
related symptoms. The questions within each FACT-L con-
struct are summated to obtain a construct score, and a final
total score is derived by adding these single summated scores.
Statistical Analysis
Fisher’s exact test tests were used to compare the
baseline and follow-up characteristics between the different
cohorts (overall, cohort I, and cohort II—Figure 1). Overall
Overall (N=186) 
QOL Completed at 
Baseline and Week 8 
(N=111)
Prior Platinum 
Therapy (N=145) 
DNA Samples 
Genotyped (N=148) 
Cohort I: DNA Samples 
Genotyped and Received 
Prior Platinum Therapy 
(N=113)
Cohort II: QOL Completed 
at Baseline and Week 8 for 
UNISCALE and FACT-L, 
DNA Samples Genotyped, 
and Received Prior 
Platinum Therapy (N=46)
FIGURE 1. Patient cohorts included in the various analyses.
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survival (OS) was defined as the time from randomization to
death from any cause. Time to disease progression (TTP) was
defined as the time from randomization to the date of first
documented disease progression. The distributions of OS and
TTP for the genotypes at each locus were estimated using the
Kaplan-Meier method.9 Multivariate Cox proportional haz-
ards models adjusted for age, gender, treatment arm, ECOG
performance score, stage, and response to initial treatment
with platinum therapy were used to evaluate the prognostic
significance of the genotypes at each locus on OS and TTP.10
Hazard ratios (HR) and 95% confidence intervals (CI) are
reported. The UNISCALE scores and the FACT-L summated
scores were transformed to a 0 to 100 scale, with higher
scores representing better status. A clinically significant de-
cline (CSD) in QOL was defined as a 10% (i.e., 10 point)
decrease from baseline to week-8. Multivariate logistic re-
gression models (adjusting for the same factors as in the Cox
models) were used to evaluate the association of the geno-
types at each locus on a CSD in QOL, and the incidence of a
severe (grade 3 or higher) AE.11 Odds ratios (OR) and 95%
CI are reported. All analyses were carried out using SAS
version 9.1.3, and p-values 0.05 were considered signifi-
cant. No adjustments for multiple comparisons were made as
these analyses are considered exploratory and hypothesis
generating due to the limited sample size.
RESULTS
There were no significant differences in the distribution
of baseline characteristics of the different cohorts (Table 1).
The median follow-up of alive patients in cohorts I and II
were similar to the overall cohort (63.2, 60.5, and 60.4
months, respectively). In cohorts I and II, 94 and 93% of
deaths were due to lung cancer, respectively. The median OS
(in months) of patients in the 3 cohorts were: 10.9 (overall),
10.6 (cohort I), and 12.4 (cohort II) months, respectively
(log-rank p  0.36).
Genotypes and Clinical Outcomes
Table 2 provides genotyping distribution of the six
DNA markers representing GSH-pathway genetic variation.
TABLE 1. Baseline Characteristics
Overall Cohort I
pa
Cohort II
pan (%) n (%) n (%)
n 186 113 46
Arm
CAI 94 (50.5) 58 (51.3) 0.91 17 (37.0) 0.10
Placebo 92 (49.5) 55 (48.7) 29 (63.0)
Median age in years (range) 66 (35–87) 65 (37–87) 0.80 67 (40–83) 0.50
Gender
Female 79 (42.5) 53 (46.9) 0.47 20 (43.5) 1.00
Male 107 (57.5) 60 (53.1) 26 (56.5)
Performance score
0 75 (40.3) 51 (45.1) 0.75 22 (47.8) 0.55
1 95 (51.1) 54 (47.8) 22 (47.8)
2 16 (8.6) 8 (7.1) 2 (4.4)
Stage
IIIA/IIIB 41 (22.0) 26 (23.0) 0.89 11 (23.9) 0.84
IV 145 (78.0) 87 (77.0) 35 (76.1)
Histology
Adeno 106 (57.0) 67 (59.3) 0.81 28 (60.9) 0.62
Bronchoalveolar/large cell 19 (10.2) 13 (11.5) 7 (15.2)
NOS NSCLC/not available 27 (14.5) 12 (10.6) 5 (10.9)
Squamous 34 (18.3) 21 (18.6) 6 (13.0)
Response to prior platinum
Complete response 8 (4.3) 5 (4.4) 0.91 3 (6.5) 0.50
Partial response 86 (46.2) 56 (49.6) 25 (54.4)
Regression 15 (8.1) 10 (8.8) 4 (8.7)
Stable 77 (41.4) 42 (37.2) 14 (30.4)
Smoking status
Never smoked 21 (11.3) 16 (14.2) 0.48b 5 (10.9) 1.00b
Former smoker 111 (59.7) 66 (58.4) 30 (65.2)
Current smoker 35 (18.8) 29 (25.7) 10 (21.7)
Missing/unknown 19 (10.2) 2 (1.8) 1 (2.2)
a Based on Fisher’s exact test except for age, which is based on the Wilcoxon Rank-Sum test.
b Missing/unknown category excluded.
NSCLC, non-small cell lung cancer; CAI, carboxyaminoimidazole.
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No statistically significant differences in the incidence of
severe AEs were observed for any of the genotypes (data not
shown). Figure 2 depicts the Kaplan-Meier survival curves by
GCLC-77 carrier status of the patients, with a median sur-
vival time of 8 months for patients with the 77 genotype
compared with 12 months for patients with other genotypes
(7* and **). The results from the multivariate Cox propor-
tional hazards models adjusted for baseline factors (see Meth-
ods section) show that, although no significant differences in
TTP were observed for any of the genotypes, patients carry-
ing a GCLC-77 repeat genotype (homozygous) had a worse
OS (HR: 1.6, p  0.05 for 77 versus 7* and **). In addition,
gender was a significant predictor of OS in all genotype
models (with males having a worse prognosis; HR 1.5–1.7;
p  0.02–0.06). Gender and age were significant predictors
of TTP in all genotype models (with males HR  1.4–1.5;
p  0.04–0.08 and patients younger than 65 years of age
HR 0.5–0.6; p  0.01 having a worse outcome).
We also tested combined effects at two loci on OS and
TTP outcomes based on our previous findings where
GCLC-77 and GSTT1-present together was a significant pre-
dictor for OS of lung cancer. Again, although none of the
combined genotypes was significant for TTP, we found
GCLC-77  GSTT1-present and GCLC-77  GPX1-CC/CT
were associated with a worse OS. However, the estimated
HR, 95% CI, and p value for combined genotypes were all
similar to that of GCLC-77 alone, suggesting it is unneces-
sary to use other SNP markers.
Genotypes and Quality of Life (QOL)
In this exploratory analysis, we systematically assessed
the association of each candidate genetic variant and CSD of
multiple QOL measures. Table 3 shows the CSD percentages
by the genotypes at each locus for UNISCALE and FACT-L
(both total and for the listed constructs); except for GCLC,
variants in each SNP showed differing association of CSD
percentage with varied QOL measures. For example, 48% of
patients with GSTM1-present genotype reported a CSD in the
UNISCALE versus 19% of those with GSTM1-null; 24%
with GSTT1-present versus 11% with GSTT1-null in the total
FACT-L; 46% with GSTP1(I105V)-AA versus 20% with
GSTP1 (I105V)-other for the functional component; 42%
with GPX1-CC versus 9% with GPX1-other for the physical
component; and 28% with GSTP1(A114V)-CC versus 14%
with GSTP1(A114V)-other for the emotional component.
When modeling each locus adjusting for the baseline
characteristics in a multivariate logistic regression model,
only the GPX1 gene showed a consistent association with
multiple QOL measures (Table 4). Specifically, patients car-
rying the GPX1-CC genotype had a CSD in the UNISCALE
(OR: 7.5; p  0.04), total FACT-L score (OR: 11.0; p 
0.04), FACT-L functional well-being construct (OR: 5.2; p
0.04), FACT-L physical well-being construct (OR: 7.1;
0
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FIGURE 2. Kaplan-Meier survival curves for
overall survival for glutamate-cysteine ligase
(GCLC) variants. a “7*” denotes the GCLC repeat
variants other than a “7.” b Multivariate Cox
Model results.
TABLE 2. Genotype Distribution
Genotype n (%)
GCLC
77 35 (31.0)
7*a 49 (43.4)
** 15 (13.3)
Failedb 14 (12.4)
GSTM1
Null 66 (58.4)
Present 47 (41.6)
GSTT1
Null 32 (28.3)
Present 81 (71.7)
GPX1
CC 45 (39.8)
TC 44 (38.9)
TT 6 (5.3)
Failedb 18 (15.9)
GSTP1 (A114V)
CC 84 (74.3)
TC 15 (13.3)
Failedb 14 (12.4)
GSTP1 (I105V)
AA 50 (44.3)
GA 41 (36.3)
GG 9 (8.0)
Failedb 13 (11.5)
a “7*” denotes the GCLC repeat variants other than a “7.”
b These patients were removed from corresponding genotype analysis.
GCLC, glutamate-cysteine ligase; GPX1, glutathione peroxidase 1; GSTP1, gluta-
thione s-transferase pi 1; GSTM1, glutathione s-transferase M1.
Yang et al. Journal of Thoracic Oncology • Volume 4, Number 4, April 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer482
TABLE 4. Multivariate Logistic Regression Models of Genotypes at 6 Loci and a CSD in QOL for the UNISCALE, FACT-L Total
Score, and FACT-L Constructsa
Genotype
UNISCALE
FACT-L
Total Score Functional Physical Emotional
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GCLCb
7*c — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
77 1.1 (0.2–4.7) 0.93 1.0 (0.2–4.5) 0.97 1.1 (0.4–5.6) 0.62 0.9 (0.2–3.6) 0.85 1.2 (0.3–5.7) 0.80
GSTM1
Null 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
Present 3.4 (0.8–15.5) 0.11 1.0 (0.2–4.9) 0.96 1.8 (0.5–7.3) 0.40 1.5 (0.3–6.4) 0.60 1.6 (0.3–7.7) 0.59
GSTT1
Null 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
present 0.6 (0.1–3.8) 0.61 2.4 (0.2–27.8) 0.49 0.9 (0.2–5.3) 0.93 1.8 (0.3–11.3) 0.54 2.8 (0.2–31.1) 0.41
GPX1
Others 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
CC 7.5 (1.2–49.3) 0.04 11.0 (1.1–109.0) 0.04 5.2 (1.1–25.2) 0.04 7.1 (1.2–41.9) 0.03 23.8 (2.1–264.6) 0.01
GSTP1
(A114V)
Others 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
CC 3.0 (0.2–38.0) 0.40 d — d — d — 1.9 (0.1–27.0) 0.62
GSTP1
(I105V)
Others 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
AA 2.9 (0.5–17.4) 0.25 0.8 (0.1–4.8) 0.78 3.3 (0.6–16.6) 0.16 2.3 (0.4–13.3) 0.33 0.4 (0.1–3.01) 0.39
a Adjusted for age, gender, performance status, treatment arm, disease stage, and response to prior platinum therapy.
b No patients with the ** variant.
c “7*” denotes the GCLC repeats variants other than a “7.”
d Unable to assess due to few numbers/sparse data.
GCLC, glutamate-cysteine ligase; FACT-L, Functional Assessment of Cancer Therapy-Lung; GSTP1, glutathione s-transferase pi 1; GSTM1, glutathione s-transferase M1;
GPX1, glutathione peroxidase 1; GSTT1, glutathione s-transferase theta 1; OR, odds ratio; CI, confidence interval.
TABLE 3. Clinically Significant Decline (CSD) Percentages for the Genotypes at each Locus for UNISCALE, Total FACT-L, and
FACT-L Constructs
Genotype UNISCALE Total FACT-L Functional Physical Emotional
GCLCa
7*b 33.3 19.2 34.6 26.9 26.9
77 33.3 25.0 35.0 25.0 25.0
GSTM1
Null 19.1 21.7 26.1 21.7 21.7
Present 47.6 21.7 43.5 30.4 30.4
GSTT1
Null 37.5 11.1 33.3 22.2 11.1
Present 32.4 24.3 35.1 27.0 29.7
GPX1
Others 19.1 9.1 22.7 9.1 13.6
CC 47.6 33.3 45.8 41.7 37.5
GSTP1 (A114V)
Others 14.3 0.0 0.0 0.0 14.3
CC 37.1 25.6 41.0 30.8 28.2
GSTP1 (I105V)
Others 21.1 20.0 20.0 20.0 25.0
AA 43.5 23.1 46.2 30.8 26.9
a No patients with the */* variant.
b “7*” denotes the GCLC repeats variants other than a “7.”
GCLC, glutamate-cysteine ligase; FACT-L, Functional Assessment of Cancer Therapy-Lung; GSTP1, glutathione s-transferase pi 1; GSTM1, glutathione s-transferase M1;
GPX1, glutathione peroxidase 1.
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p  0.03), and FACT-L emotional well-being construct (OR:
23.8; p  0.01). The CI for these associations was relatively
wide (possibly due to sparse data). We also systematically
evaluated the association of combined SNP loci and a CSD in
QOL measures based on the distribution of the CSD percent-
ages by the genotypes at each locus in Table 3 using multi-
variate logistic regression models. Results of two combined
genotypes between GPX1 and GSTP1 are presented in Table
5, confirming the same association as GPX1 alone.
Other constructs within the FACT-L, i.e., social and
family, and additional concerns were not significantly asso-
ciated with any of the genotypes (data not shown).
DISCUSSION
Two major categories of targeted therapy are tumor-
specific and patient-specific treatment modalities.12 Tumor-
specific targets are usually developed based on changes in
angiogenesis pathways, apoptosis, proteosome regulation,
and cell cycle control; particularly in the recent literature are
alterations in the tyrosine kinase receptors and vascular en-
dothelial growth factor.13 Results from our current study
support previous reports that genomic variations of patients,
representing patient-specific genomic markers, affect OS.
Specifically, we have validated our previous findings that
variants in the GCLC gene that encodes the rate-limiting
enzyme GCS in the GSH pathway could make a differ-
ence in OS of patients who received platinum-based che-
motherapy.
As an ancillary correlative study based on NCCTG-97-
24-51, which was a negative and early terminated phase III
trial,4 we took advantage of the design where most subjects
were previously treated with platinum drugs and had well-
documented responses, AEs, times to progression, and sur-
vival. An a priori hypothesis was that genomic variations
representing platinum drug metabolizing functions may pre-
dict clinical outcome independent of other known factors.
Among the six carefully selected GSH-related polymorphic
markers, either SNPs or short-tandem repeats, we confirmed
that GCLC repeats variation was significantly associated with
OS in this study; specifically, patients with GCLC-77 geno-
type had a worse OS outcome compared with those with other
genotypes. This result is biologically plausible because
GCLC encodes the catalytic function of a rate-limiting en-
zyme in GSH synthesis; the mechanisms where how GSH
level and activity affect platinum drug efficacy has been
previously reviewed.1
It is not a surprise that we did not find TTP and AEs to
be associated with the candidate genomic variations. The
NCCTG-97-24-51 trial selection entry criteria excluded those
who had progressed on platinum drugs (only patients who
were stable or responding were randomized to CAI or a
placebo). The AEs (primarily grade 1 and 2) were experi-
enced more often by patients in the CAI arm,4 and it is
unlikely that AEs related to CAI would bear a confounding
effect on the association of OS and GCLC-77 genotype.
In parallel to the ongoing efforts in effectively treating
advanced lung cancer as a disease, QOL of survivors has
always been an important concern of patients and care pro-
viders, and has been an increasing focus in the medical
community. It is inevitable that both the quantity and the
QOL of lung cancer patients needs to be carefully evaluated
and balanced when declaring a new treatment superior to the
existing ones or receiving any chemotherapy. If a feasible test
of genomic markers could predict the impact of chemother-
apy on major domains of QOL, it could assist patients and
physicians in decisions and preparation before choosing treat-
ment plans. In the current study, we conducted exploratory
analyses of the potential predictive value using ORs for the
same candidate markers under evaluation for clinical out-
comes. From multivariate logistic models under each QOL
construct, total or subscales, variations at the GPX1 locus
showed the most significant association with CSD percent-
age, with improved OR measures when combined with vari-
ations at the GSTP1 gene. Five QOL measures associated
with genetic variations are UNISCALE, total FACT-L, phys-
ical well-being, functional well-being, and emotional well-
being constructs. The Physical construct deals with the as-
pects like energy, pain, and side effects from treatment;
whereas the functional construct deals with mobility and
general outlook on life.
TABLE 5. Multivariate Logistic Regression Model for Selected Genotype Combinations and a CSD in QOL for the UNISCALE,
FACT-L Total Score, and FACT-L Constructsa
Genotype Combinations
UNISCALE
FACT-L
Total Score Functional Physical Emotional
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
GPX1/GSTP1(A114V)
Others (n  26, 57%) 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
CC/CC (n  20, 43%) 8.2 (1.3–51.9) 0.02 46.4 (2.2–967.6) 0.01 10.4 (1.9–58.5) 0.01 12.9 (2.0–83.7) 0.01 21.4 (1.9–247.2) 0.01
GPX1/GSTP1(I105V)/GSTP1
(A114V)
Other (n  35, 76%) 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) — 1.0 (–) —
CC/AA/CC (n  11, 24%) 6.0 (1.0–35.9) 0.05 3.3 (0.5–20.0) 0.19 6.1 (1.2–31.7) 0.03 5.6 (1.1–27.8) 0.04 3.5 (0.5–22.3) 0.19
a Adjusted for age, gender, performance status, treatment arm, disease stage, and response to prior platinum therapy.
GPX1, glutathione peroxidase 1; GSTP1, glutathione s-transferase pi 1; OR, odds ratio; CI, confidence interval; FACT-L, Functional Assessment of Cancer Therapy-Lung; QOL,
quality of life; CSD, clinically significant decline.
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Our findings are among the pioneer work in linking
genetic variations to QOL measures. To note, NCCTG inves-
tigators previously correlated allelic variants in 5-FU metab-
olizing genes with QOL in colorectal cancer patients.14 Un-
like GCLC locus variations and OS, plausible mechanisms
and interpretations of the association between genomic vari-
ations and CSD percentage are underdeveloped. Although
direct causal relationship is far reaching, several indirect
“pathways” are postulated. First, our results are based on
relatively small samples with wide confidence intervals;
chance findings are not ruled out until robust replicate results
become available. Second, although the CSD percentage was
derived based on patient-reported QOL scores, the CSD
percentage in only two specific constructs (physical and
functional) along with total FACT-L and UNISCALE are
significantly associated with GPX1/GSTP1 SNPs, indicating
the underlying physical and functional conditions that drive
the decline in these constructs may be associated with these
genes. Third, GPX1 and GSTP1 genes may be surrogates for
yet to be discovered “QOL genes.” Beyond cautious inter-
pretation of results from a small study and based on limited
evidence in experimental models, we hypothesize that there
are likely downstream immune response effects modulated by
GPX1 expression and activity levels. In transgenic mice that
overexpress human antioxidant enzymes (particularly intra-
cellular GSH peroxidase), the mechanism of protection in-
volves the modulation of inflammatory response as well as
reduced sensitivity of neurons to cytotoxic cytokines.15 These
animals show significant reduction of expression of che-
mokines, IL-6, and cell death-inducing ligands as well as
corresponding receptors. One well known inflammation path-
way includes nuclear factor-kappaB (NFkappaB), which can
be inhibited by GPX1 expression.16 Nonetheless, the appli-
cations of reliable and accurate predictive genetic markers
may not require fully understanding their biologic mecha-
nisms.
In conclusion, although the addition of CAI after che-
motherapy does not provide clinical benefit or improvement
in QOL over a placebo in advanced NSCLC, genotypes of
GSH-related enzymes, especially GCLC, may be used as host
factors in predicting patients’ survival after platinum-based
chemotherapy. Meanwhile, GPX1 may be an inherited factor
in predicting patients’ QOL after platinum-based chemother-
apy. Furthermore, investigations to define and measure the
effects of these genes in chemotherapeutic regimens, drug
toxicities, disease recurrence or progression, and measure the
direct or indirect effects of these genes on QOL are critical.
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